Asthma therapies
-
Valeo Pharma’s CEO Steve Saviuk Talks about Record FQ4 & F2022 Revenue Up 274% & 105%, Respectively
In this InvestorIntel interview, Tracy Weslosky talks to Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO,…
-
Record revenues in 2022 of $27.7 million, Valeo Pharma investment in commercial infrastructure starts to pay off
What a difference a year makes. Last year at this time we were heading into wave something or…
-
Steve Saviuk of Valeo Pharma talks about acquiring new therapeutic drugs and record Q3 revenue
In this interview, InvestorIntel Publisher and Editor in Chief Stephen Lautens talks to Valeo Pharma Inc.’s (TSX: VPH…
-
Valeo Pharma’s rocketing growth in sales points to positive cash flow this year
Stock market investors love companies that can quickly expand and rapidly grow their revenues. The very best of…
-
Steve Saviuk of Valeo Pharma on record 2021 revenues, achieving breakeven in 2022, and uplisting on the TSX
In a recent InvestorIntel interview, Tracy Weslosky spoke with Steve Saviuk, CEO of Valeo Pharma Inc. (CSE: VPH | OTCQB:…
